Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes

a En representacion del Grupo de Trabajo de Consensos y Guias Clinicas de la Sociedad Espanola de Diabetes, Espana b Sociedad Espanola de Arteriosclerosis (SEA), Espana c Sociedad Espanola de Cardiologia (SEC), Espana d Sociedad Espanola de Endocrinologia y Nutricion (SEEN), Espana e Sociedad Espanola de Farmacia Comunitaria (SEFAC), Espana f Sociedad Espanola de Medicina Familiar y Comunitaria (SEMFYC), Espana g Sociedad Espanola de Medicina Interna (SEMI), Espana h Sociedad Espanola de Medicos de Atencion Primaria (SEMERGEN), Espana i Sociedad Espanola de Medicos Generales y de Familia (SEMG), Espana j Sociedad Espanola de Nefrologia (SEN), Espana

• Publication year

  2011

• Venue

  Endocrinología y Nutrición (English Edition)

• Publication date

  2011-01-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/S2173-5093(11)70022-8
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Pioglitazone

  2012cited by this paper
• A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs

  2010cited by this paper
• Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

  2010cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009cited by this paper
• Hyperglycemic Crises in Adult Patients With Diabetes

  2009cited by this paper
• Three-year efficacy of complex insulin regimens in type 2 diabetes.

  2009cited by this paper
• Earlier triple therapy with pioglitazone in patients with type 2 diabetes

  2009cited by this paper
• Effects of Intensive Glucose Lowering in Type 2 Diabetes

  2009cited by this paper
• Long‐term glycaemic control with metformin–sulphonylurea–pioglitazone triple therapy in PROactive (PROactive 17)

  2009cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

  2009cited by this paper
• Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.

  2009cited by this paper
• Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

  2009cited by this paper
• Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin

  2009cited by this paper
• Insulin-Based Versus Triple Oral Therapy for Newly Diagnosed Type 2 Diabetes

  2009cited by this paper
• A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.

  2009cited by this paper
• Glucose control and vascular complications in veterans with type 2 diabetes.

  2009cited by this paper
• Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

  2009cited by this paper
• Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.

  2009cited by this paper
• Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

  2009cited by this paper
• Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.

  2009cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Effect of a multifactorial intervention on mortality in type 2 diabetes.

  2008cited by this paper
• Effects of Intensive Glucose Lowering in Type 2 Diabetes The Action to Control Cardiovascular Risk in Diabetes Study Group

  2008cited by this paper
• Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

  2008cited by this paper
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes

  2008cited by this paper
• Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin.

  2008cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?

  2008cited by this paper
• Meglitinide analogues for type 2 diabetes mellitus.

  2007cited by this paper
• The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes

  2007cited by this paper
• A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

  2007cited by this paper
• Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes

  2007cited by this paper
• Exploring Treatment Strategies for Type 2 Diabetes

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

  2007cited by this paper
• Defining the Role of Repaglinide in the Management of Type 2 Diabetes Mellitus

  2007cited by this paper
• [Commentary to the article: Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43].

  2007cited by this paper
• Improvement in glycaemic control with rosiglitazone/metformin fixed‐dose combination therapy in patients with type 2 diabetes with very poor glycaemic control

  2006cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

  2006cited by this paper
• Meglitinide analogues: a review of clinical data focused on recent trials.

  2006cited by this paper
• Efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes

  2006cited by this paper
• Safety of Type 2 Diabetes Treatment With Repaglinide Compared With Glibenclamide in Elderly People

  2006cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials*

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes.

  2005cited by this paper
• Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.

  2005cited by this paper
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• Highlights of the 2003 Clinical Practice Guidelines for the prevention and management of diabetes in Canada.

  2004cited by this paper
• Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.

  2004cited by this paper
• Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

  2004cited by this paper
• All‐cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides

  2004cited by this paper
• Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent: a systematic evaluation of triple oral therapy in a minority population.

  2004cited by this paper
• Short-Term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes

  2004cited by this paper
• Real World Effectiveness of Rosiglitazone Added to Maximal (Tolerated) Doses of Metformin and a Sulfonylurea Agent: Response to De

  2004cited by this paper
• The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

  2003cited by this paper
• Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

  2003cited by this paper
• Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.

  2002cited by this paper
• Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

  2002cited by this paper
• Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes

  2002cited by this paper
• Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

  2002cited by this paper
• Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide

  2001cited by this paper
• Oral antidiabetic treatment in patients with coronary disease: Time‐related increased mortality on combined glyburide/metformin therapy over a 7.7‐year follow‐up

  2001cited by this paper
• Insulin resistance and its treatment by thiazolidinediones.

  2001cited by this paper
• The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes.

  2001cited by this paper
• Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study

  2000cited by this paper
• Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

  1999cited by this paper
• Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus

  1999cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

  1995cited by this paper
• Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

  1995cited by this paper
• Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations: A double-blind controlled study

  1994cited by this paper
• One year comparative trial of metformin and glipizide in type 2 diabetes mellitus.

  1994cited by this paper
• Comparative Tolerability Profiles of Oral Antidiabetic Agents

  1994cited by this paper

• Individualized Glycemic Control in Type 2 Diabetic Patients in Iran: A Multi-Center Data Analysis

  2023cites this paper
• ENDOCRINOLOGÍA Y NUTRICIÓN Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus (cid:2)

  2022cites this paper
• ENDOCRINOLOGÍA Y NUTRICIÓN Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus (cid:2)

  2022cites this paper
• Canagliflozin improves glycemic control and body weight and reduces insulin doses in patients with type 2 diabetes treated with insulin in real practice

  2019cites this paper
• INTEGRA study protocol: primary care intervention in type 2 diabetes patients with poor glycaemic control

  2019cites this paper
• Calculating individualized glycaemic targets using an algorithm based on expert worldwide diabetologists: Implications in real‐life clinical practice

  2018cites this paper
• Diabetes in prisons: improving its management.

  2017cites this paper
• Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus

  2016cites this paper
• Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.

  2016cites this paper
• Meeting individualized glycemic targets in primary care patients with type 2 diabetes in Spain

  2016cites this paper
• Estudio observacional prospectivo con insulina detemir en pacientes con diabetes mellitus tipo 2 mal controlados que inician por primer vez tratamiento con insulina (estudio SOLVE)

  2015cites this paper
• Breaking Therapeutic Inertia in Type 2 Diabetes: Active Detection of In-Patient Cases Allows Improvement of Metabolic Control at Midterm

  2015cites this paper
• Effectiveness of therapy with basal insulin analogs to improve glycemic control in type 2 diabetes mellitus patients poorly controlled with oral antidiabetic drugs in combination or not with NPH insulin

  2013cites this paper
• Proton pump inhibitors: impact on glucose metabolism

  2013cites this paper
• Evolution of Biochemical Effects of Byetta® in Type 2 Diabetics with Cardiovascular Risk

  2013cites this paper
• ENDOCRINOLOGÍA Y NUTRICIÓN

  year unknowncites this paper